← Back to Clinical Trials
Recruiting NCT06707402

NCT06707402 The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06707402
Status Recruiting
Phase
Sponsor University of Aarhus
Condition Parkinson Disease
Study Type INTERVENTIONAL
Enrollment 129 participants
Start Date 2025-03-11
Primary Completion 2027-08-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
WALKACTIVECON

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 129 participants in total. It began in 2025-03-11 with a primary completion date of 2027-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to investigate if brisk walking can improve walking function in people with Parkinson's disease and what kind of brisk walking intervention that is most effective. The main questions are: If brisk walking can reduce self-perceived walking difficulty What type of exercise intervention is most effective. Researchers will compare a brisk walking group receiving a personalized walking program with a group receiving an activity tracker and a control group. Participants will * be tested at baseline (0 weeks), post the intervention period (24 weeks) and after a follow-up period (48 weeks). * be randomly allocated to one of three groups at baseline. * follow the prescribed intervention they are allocated to.

Eligibility Criteria

Inclusion Criteria: 1. clinically diagnosed with Parkinson's disease 2. aged ≥40 years 3. Hoehn and Yahr stage ≤3 4. able to independently undertake transportation back and forth from test days and training sessions 5. expectedly able to complete ≥85% of the training sessions 6. experience walking difficulties (the generic walking scale (Walk-12G) score ≥8.5). Exclusion Criteria: 1. have another neurological disorder or other disorders that affect gait and balance (e.g., severe arthritis or arthrosis) 2. are pregnant 3. have dementia (Montreal Cognitive Assessment score \<18) 4. are suffering from alcohol abuse (i.e., exceeding ten units per week, according to the Danish Health Authority recommendation 5. have cardiovascular, respiratory, orthopedic, or metabolic disorders or other medical comorbidities hindering participation in maximal exercise testing. 6. have a depression 7. use an activity tracker during exercise 8. performing high-intensity brisk walking three or more times during a week.

Contact & Investigator

Central Contact

Frederik B Jensen, MSc

✉ fbj@ph.au.dk

📞 +4521268252

Frequently Asked Questions

Who can join the NCT06707402 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06707402 currently recruiting?

Yes, NCT06707402 is actively recruiting participants. Contact the research team at fbj@ph.au.dk for enrollment information.

Where is the NCT06707402 trial being conducted?

This trial is being conducted at Aarhus C, Denmark.

Who is sponsoring the NCT06707402 clinical trial?

NCT06707402 is sponsored by University of Aarhus. The trial plans to enroll 129 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology